Why the study?
Clinical guidance for competitive sports participation in athletes with genetic cardiomyopathies needed to move away from blanket sports disqualifications toward athlete-specific context, shared decision-making, and genotype-informed risk assessment.
This updated AHA/ACC/ACSM scientific statement shifts clinical practice from blanket sports disqualifications toward individualized, genotype-informed risk assessment and shared decision-making for competitive athletes with genetic cardiomyopathies.
Answers are grounded in this paper and cite their sources.
Shifts eligibility decisions from disqualification to individualized, genotype-informed assessment in athletes with cardiomyopathies; extends 2020 consensus with shared decision-making emphasis.
The updated AHA/ACC Scientific Statement on Clinical Considerations for Competitive Sports Participation for Athletes with Cardiovascular Conditions presents the clinical considerations for athletes with genetic cardiomyopathies, including hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation. This ACSM Official Pronouncement complements the 2020 ACC/AHA Scientific Statement by providing athlete-specific context, practical guidance for shared decision-making, and genotype-informed risk assessment for competitive sports participation, moving away from blanket sports disqualifications. Sports participation recommendations for each condition are tailored to risk levels, symptomatology, and genotype. Regular follow-ups and close surveillance are advised. This evolving approach underscores the importance of individualized care, ongoing research, and the integration of new data to better inform shared decision-making on the risks and benefits of competitive sports in athletes with cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Gati et al. (2026) studied Genetic cardiomyopathies (hypertrophic, dilated, arrhythmogenic, and left ventricular hypertrabeculation) in competitive athletes. Shared decision-making and genotype-informed risk assessment for competitive sports participation was evaluated. The updated AHA/ACC Scientific Statement recommends individualized, genotype-informed risk assessment and shared decision-making rather than blanket sports disqualifications in athletes.
Synapse has enriched 10 related papers. Consider them for comparative context: